methotrexate

FDA Drug Profile — Otrexup, METHOTREXATE, Rasuvo, Methotrexate

methotrexate is listed in the FDA National Drug Code directory with 26 NDC codes, marketed under brand names including Otrexup, METHOTREXATE, Rasuvo. Available dosage forms: injection, solution, tablet, powder.

Drug details

Generic Name
methotrexate
Brand Names
Otrexup, METHOTREXATE, Rasuvo, Methotrexate
Application Number
NDA204824
Sponsor
Antares Pharma, Inc.
NDC Codes
26
Dosage Forms
INJECTION, SOLUTION, TABLET, POWDER
Routes
SUBCUTANEOUS, INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS, ORAL
Active Ingredients
METHOTREXATE, METHOTREXATE SODIUM

Indications and Usage

1 INDICATIONS AND USAGE Methotrexate Injection is a folate analog metabolic inhibitor indicated for The following neoplastic diseases for the: Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen ( 1.1 ) Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia ( 1.2 ) Treatment of adult and pediatric patients with non-Hodgkin lymphoma ( 1.3 ) Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen ( 1.4 ) Treatment of adults with breast cancer as part of a combination chemotherapy regimen ( 1.5 ) Treatment of adults with squamous cell carcinoma of the head and neck as single-agent ( 1.6 ) Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen ( 1.7 ) Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) Treatment of adults with severe psoriasis. ( 1.10 ) 1.1 Acute Lymphoblastic Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen. 1.2 Meningeal Leukemia: Prophylaxis and Treatment Methotrexate Injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. 1.3 Non-Hodgkin Lymphoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin lymphoma. 1.4 Osteosarcoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. 1.5 Breast Cancer Methotrexate Injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen. 1.6 Squamous Cell Carcinoma of the Head and Neck Methotrexate Injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single-agent. 1.7 Gestational Trophoblastic Neoplasia Methotrexate Injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (GTN) as part of a combination chemotherapy regimen. 1.8 Rheumatoid Arthritis Methotrexate Injection is indicated for the treatment of adults with rheumatoid arthritis (RA). 1.9 Polyarticular Juvenile Idiopathic Arthritis Methotrexate Injection is indicated for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA). 1.10 Psoriasis Methotrexate Injection is indicated for the treatment of adults with severe psoriasis.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.